Evogene Partners with Shanghai Lishan Biopharmaceuticals for Groundbreaking Cancer Therapy Evogene and Shanghai Lishan Biopharmaceuticals have entered into an exclusive collaboration to advance BMC128, a microbiome-based cancer treatment showing promising early results in clinical studies.

Evogene Partners with Shanghai Lishan Biopharmaceuticals for Groundbreaking Cancer Therapy #Israel #Rehovot #Evogene #Lishan_Biotech #BMC128